Literature DB >> 23250454

[Insulin therapy of diabetes].

Monika Lechleitner1, Michael Roden, Raimund Weitgasser, Bernhard Ludvik, Peter Fasching, Friedrich Hoppichler, Alexandra Kautzky-Willer, Guntram Schernthaner, Rudolf Prager, Thomas C Wascher.   

Abstract

Hyperglycemia contributes to morbidity and mortality in patients with diabetes. Thus, reaching treatment targets with regard to control of glycemia is a central goal in the therapy of diabetic patients. The present article represents the recommendations of the Austrian Diabetes Association for the practical use of insulin according to current scientific evidence and clinical studies.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23250454     DOI： 10.1007/s00508-012-0266-2

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN： 0043-5325            Impact factor:   1.704


  30 in total

Review 1.  Standards of medical care in diabetes--2012.

Authors: 
Journal:  Diabetes Care       Date:  2012-01       Impact factor: 19.112

2.  Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  S E Inzucchi; R M Bergenstal; J B Buse; M Diamant; E Ferrannini; M Nauck; A L Peters; A Tsapas; R Wender; D R Matthews
Journal:  Diabetologia       Date:  2012-04-20       Impact factor: 10.122

3.  Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.

Authors:  David M Nathan; Patricia A Cleary; Jye-Yu C Backlund; Saul M Genuth; John M Lachin; Trevor J Orchard; Philip Raskin; Bernard Zinman
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

Review 4.  Management of diabetes mellitus: is the pump mightier than the pen?

Authors:  John C Pickup
Journal:  Nat Rev Endocrinol       Date:  2012-02-28       Impact factor: 43.330

5.  Concomitant oral antihyperglycemic agent use and associated treatment outcomes after initiation of insulin therapy.

Authors:  William H Herman; John B Buse; Richard F Arakaki; Kathleen M Dungan; Honghua H Jiang; Jennie G Jacobson; Jessie L Fahrbach
Journal:  Endocr Pract       Date:  2011 Jul-Aug       Impact factor: 3.443

6.  Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus.

Authors: 
Journal:  JAMA       Date:  2002-05-15       Impact factor: 56.272

7.  Three-year efficacy of complex insulin regimens in type 2 diabetes.

Authors:  Rury R Holman; Andrew J Farmer; Melanie J Davies; Jonathan C Levy; Julie L Darbyshire; Joanne F Keenan; Sanjoy K Paul
Journal:  N Engl J Med       Date:  2009-10-22       Impact factor: 91.245

Review 8.  Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus.

Authors:  A N Goudswaard; N J Furlong; G E H M Rutten; R P Stolk; G D Valk
Journal:  Cochrane Database Syst Rev       Date:  2004-10-18

9.  QTc interval prolongation is independently associated with severe hypoglycemic attacks in type 1 diabetes from the EURODIAB IDDM complications study.

Authors:  Gabriella Gruden; Sara Giunti; Federica Barutta; Nish Chaturvedi; Daniel R Witte; Marinella Tricarico; John H Fuller; Paolo Cavallo Perin; Graziella Bruno
Journal:  Diabetes Care       Date:  2011-11-28       Impact factor: 19.112

Review 10.  Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  Silvio E Inzucchi; Richard M Bergenstal; John B Buse; Michaela Diamant; Ele Ferrannini; Michael Nauck; Anne L Peters; Apostolos Tsapas; Richard Wender; David R Matthews
Journal:  Diabetes Care       Date:  2012-04-19       Impact factor: 19.112
View more
  1 in total

1.  Self-reported frequency and impact of hypoglycaemic events in insulin-treated diabetic patients in Austria.

Authors:  Raimund Weitgasser; Sandra Lopes
Journal:  Wien Klin Wochenschr       Date:  2014-11-25       Impact factor: 1.704
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.